The International Journal of Neuropsychopharmacology



Brief Reports

Risperidone augmentation in treatment-resistant obsessive–compulsive disorder: a double-blind, placebo-controlled study


Eric Hollander a1c1, Nicolò Baldini Rossi a1a2, Erica Sood a1 and Stefano Pallanti a1a3
a1 Department of Psychiatry, The Mount Sinai School of Medicine, New York, NY, USA
a2 Department of Psychiatry, Neurobiology, Pharmacology and Biotechnology, University of Pisa, Italy
a3 Department of Psychiatric and Neurological Sciences, University of Florence, Italy

Article author query
hollander e   [PubMed][Google Scholar] 
rossi n   [PubMed][Google Scholar] 
sood e   [PubMed][Google Scholar] 
pallanti s   [PubMed][Google Scholar] 

Abstract

This double-blind, placebo-controlled trial was performed to determine the efficacy and tolerability of 8 wk of risperidone augmentation of serotonin reuptake inhibitor (SRI) treatment in adult subjects with treatment-resistant obsessive–compulsive disorder (OCD) (failure of at least two SRI trials). Sixteen adult treatment-resistant OCD patients were randomly assigned to augmentation with 8 wk of either risperidone (n=10) (0.5–3.0 mg/d) or placebo (n=6) following at least 12 wk of SRI treatment. Four patients on risperidone (40%) and none (0%) on placebo were responders with both a Clinical Global Impression – Improvement (CGI-I) score of 1 or 2 and a Yale–Brown Obsessive–Compulsive Scale (Y-BOCS) decrease [gt-or-equal, slanted]25%. Risperidone was generally well tolerated: there were 3 dropouts, 1 on risperidone and 2 on placebo. Better Y-BOCS insight score at baseline significantly correlated with a greater CGI-I score at endpoint on risperidone augmentation. Risperidone may be an effective and well-tolerated augmentation strategy in treatment-resistant OCD subjects, but larger sample size studies are required to demonstrate this.

(Received August 26 2002)
(Reviewed December 22 2002)
(Revised May 13 2003)
(Accepted May 18 2003)


Key Words: Compulsions; obsessions; obsessive–compulsive disorder; risperidone; treatment resistant.

Correspondence:
c1 Dr E. Hollander, Department of Psychiatry, Box 1230, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, NY 10029, USA. Tel.: 212-241-3623 Fax: 212-987-4031 E-mail: eric.hollander@mssm.edu